Overview

PK Study of Melphalan HCL & Alkeran for Injection of MA Conditioning in MM Patients of Autologous Transplantation

Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
To assess and compare the pharmacokinetics of Melphalan HCL for Injection (Propylene Glycol-Free) versus Alkeran for Injection in multiple myeloma (MM) patients undergoing autologous stem cell transplant (ASCT).
Phase:
Phase 2
Details
Lead Sponsor:
Acrotech Biopharma LLC
Spectrum Pharmaceuticals, Inc
Treatments:
Melphalan